Russian cancer centers track breast cancer drug results
NCT ID NCT07281001
Summary
This study collects real-world information from 60 Russian breast cancer patients who have already received trastuzumab deruxtecan treatment. Researchers will review medical records to understand how well the drug works in everyday clinical practice. The goal is to learn about treatment effectiveness and safety for patients with advanced HER2-positive breast cancer in Russia.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation
RECRUITINGMoscow, 115522, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.